Milestone Scientific Announces 2011 First Quarter Results

Instrument Sales Increase 35% to $811,000 from $600,000 in the first Quarter 2011

Management to Host Teleconference Tuesday, May 10, 2011 at 4:15 PM, EDT

LIVINGSTON, N.J., May 9, 2011 /PRNewswire/ -- Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in advanced drug delivery technologies, today announced its results for the first quarter ended March 31, 2011.

Financial Highlights When Comparing 3-Months Ended March 31, 2011 with 3-Months Ended March 31, 2010:

    --  Total revenues were $2.43 million, a decrease of 5% from $2.56 million.
            --  Sales in the U.S. increased 9% to $1.31 million from $1.20
            --  International sales decreased 18% to $1.11 million from $1.36
            --  Instrument sales increased 35% to $811,000 from $600,000.
            --  Disposable handpiece sales decreased 18% to $1.58 million from
                $1.94 million.
    --  Gross profit margin was 64% in 2011 as compared to 65% in 2010.
    --  Net loss for the first quarter ended March 31, 2011, was $141,644 as
        compared to a net profit of $83,922 for the same period in 2010. The
        $225,566 decrease in net profit was primarily attributable to a
        reduction in international handpiece sales in the first quarter of 2011
        due to the delay in obtaining registration of the WAND/STA instrument
        and handpieces for the sale of these products in China and an increase
        of $82,553 of selling general and administrative expenses in the areas
        of sales and marketing expenses, as the company continues its field
        hygienist program.
    --  Total revenues in the first quarter ended March 31, 2010 included
        $494,208 of handpiece revenue to a Chinese distributor.. Comparatively,
        exclusion of handpiece revenues to a Chinese distributor in 2010 would
        have resulted in an increase in revenues in 2011 over 2010 of $357,618.
        The expectation is that the Chinese distributor will receive regulatory
        approval to distribute the WAND/STA instrument and handpieces in 2011.

As of March 31, 2011, Milestone had $155,263 in cash and negative working capital of $177,786, and a total shareholders' equity of approximately $2.29 million. The negative working capital is due to an increase in advances to, and payable to, a contract manufacturer due to a delay in shipping the STA instruments to a Chinese distributor. The delay was caused by the distributor not yet receiving regulatory approval to sell the instruments in China. The delay in receiving regulatory approval in China also resulted in the delay of the Chinese distributor paying in total for the shipment of instruments from June 2010. The original purchase order for the instruments did not include a condition for delayed payments.

According to Leonard Osser, Chief Executive Officer of Milestone Scientific, "The first quarter of 2011 is showing the continued expansion of our instrument sales into the domestic market. Our continued focus on Group Dental Practices is beginning to demonstrate positive growth. With the addition of Towncare Partners as our first significant group practice to incorporate the WAND/STA instrument and handpieces into their practice as a new standard of care, replacing the 160 year-old syringe, our opportunity for growth in this market is significant. With the field support of our independent hygienists, providing education and training, we believe that significant growth of handpiece sales in the near future can be achieved.  Internationally, instrument sales also increased by over $100,000 as the Company continue to enter new markets and expand growth in the existing international arena. We remain optimistic that the delay in obtaining regulatory approval to sell our instruments and handpieces in China will be resolved in 2011. Therein allowing, the solid foundations created in the prior year to provide a platform for growth into 2011."

Adding to Leonard Osser's sentiments, Joseph D'Agostino, Chief Financial Officer of Milestone Scientific added, "The comparison of the first quarter 2011 to the same period in 2010, identifies substantial instrument revenue growth in both the domestic and international businesses. However, instrument growth alone is not our mission. Acceptance of the WAND/STA instrument is only the first step in the growth of our dental business. The exclusive use of the WAND/STA instrument, as the standard of care for all injections and the expansion of our handpiece usage is paramount.  Milestone is focused and committed to the hygienist/educator program in the domestic market. We believe that the investment in this program education, training and support of the dentists will reap significant benefits for the Company in the future years."

Milestone's executive management team will host a teleconference on Tuesday, May 10, 2011, beginning at 4:15 PM, EDT, and invites all interested parties to join them in a discussion regarding the Company's financial results, corporate progress and other meaningful developments. The conference call can be accessed via telephone by dialing toll free 1-888-549-7704. For those unable to participate at that time, a replay of the teleconference can be accessed domestically by dialing 1-800-406-7325 and entering the pass code 4438435. The replay will be available for 90 days.




                                             March 31, 2011  December 31, 2010



Current Assets:

Cash and cash equivalents                    $ 155,263       $ 627,082

Accounts receivable, net of allowance for
doubtful accounts of $202,160 in 2011 and
2010                                         1,380,195       796,221

Inventories                                  850,708         986,947

Advances to contract manufacturer, current   728,509         730,491

Prepaid expenses and other current assets    243,304         247,465

Total current assets                         3,357,979       3,388,206

Accounts receivable-long term, net of
allowance for doubtful accounts of $426,840
as of March 31, 2011

and $438,840 as of December 31, 2010         273,160         361,160

Advances to contract manufacturer, non
current                                      2,227,837       1,713,794

Investment in distributor, at cost           76,319          76,319

Furniture, Fixtures & Equipment net of
accumulated depreciation of $431,769 as of
March 31, 2011

and $426,482 as of December 31, 2010         63,903          66,936

Patents, net of accumulated amortization of
$316,239 as of March 31, 2011

and $294,934 as of December 31, 2010         935,717         944,858

Other assets                                 41,081          57,750

Total assets                                 $ 6,975,996     $ 6,609,023


Current Liabilities:

Accounts payable - short term                $ 2,885,994     $ 2,883,587

Accrued expenses and other payable           649,771         511,304

Total current liabilities                    3,535,765       3,394,891

Long-term Liabilities:

Accounts payable - long term                 710,162         440,376

Notes Payable-net of discount of $7,662 and
$8,361, respectively                         442,338         441,639

Total long-term liabilities                  1,152,500       882,015

Commitments and Contingencies

Stockholders' Equity

Common stock, par value $.001; authorized
50,000,000 shares; 15,030,459 shares issued

642,847 shares to be issued and 14,997,126
shares outstanding as of March 31, 2011;

14,915,959 shares issued, 637,013 shares to
be issued, and 14,882,626 shares outstanding

as of December 31, 2010                      15,673          15,552

Additional paid-in capital                   62,703,180      62,606,043

Accumulated deficit                          (59,519,606)    (59,377,962)

Treasury stock, at cost, 33,333 shares       (911,516)       (911,516)

Total stockholders' equity                   2,287,731       2,332,117

Total liabilities and stockholders' equity   $ 6,975,996     $ 6,609,023




                                                 Three Months Ended March 31,

                                                 2011         2010

Product sales, net                               $ 2,425,988  $ 2,562,578

Cost of products sold                            879,588      900,712

Gross profit                                     1,546,400    1,661,866

Selling, general and administrative expenses     1,624,255    1,541,702

Research and development expenses                43,718       88,464

Total operating expenses                         1,667,973    1,630,166

(Loss) income from operations                    (121,573)    31,700

Other (expense) income

Other income                                     -            61,916

Interest expense                                 (19,386)     (9,343)

Amortization of debt issuance                    (699)        (699)

Interest income                                  14           348

Total other (expenses) income                    (20,071)     52,222

Net (loss) income applicable to common
stockholders                                     $ (141,644)  $ 83,922

Net (loss) income per share applicable to common
stockholders -

Basic                                            $ (0.01)     $ 0.01

Diluted                                          $ (0.01)     $ 0.01

Weighted average shares outstanding and to be
issued -

Basic                                            14,875,541   13,875,278

Diluted                                          14,875,541   14,320,821

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering advanced computer-controlled drug delivery technologies for the medical and dental markets; and currently sells its award-winning products through a global distribution network serving North and South America, Asia, Africa and Europe. For more information on the STA System and other innovative Milestone products, please visit the Company's websites found at and

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2010. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Milestone Scientific Inc.
Joseph D'Agostino, Chief Financial Officer
For Media Inquiries: Laura Kaunitz, Office Manager
973-535-2717 or via e-mail at

SOURCE Milestone Scientific Inc.